

**insulin detemir (Levemir<sup>®</sup>)**  
**Novo Nordisk**

**No. 110/04**

## Summary of Advice

9 August 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

**Advice:** following a full submission.

Insulin detemir is accepted for restricted use within NHS Scotland for the treatment of diabetes mellitus.

Insulin detemir is an acceptable basal insulin for patients with diabetes mellitus. Its use should be targeted on patients attempting to achieve better hypoglycaemic control as there may be some benefit related to a reduced intra-individual variation in glycaemic profile for insulin detemir compared with established insulins. It appears to be cost-effective from the base-case of economic modelling, but this is limited by the degree of extrapolation involved and the associated width of the confidence intervals.

Professor David H Lawson  
Chairman